Furmonertinib
FURMO-002
Phase 1 small_molecule active
Quick answer
Furmonertinib for Non-Small Cell Lung Cancer (NSCLC) is a Phase 1 program (small_molecule) at ArriVent BioPharma with 1 ClinicalTrials.gov record(s).
Program details
- Company
- ArriVent BioPharma
- Indication
- Non-Small Cell Lung Cancer (NSCLC)
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active